Vaxcyte PCVX
United StatesHealthcare · BiotechnologyUSD
110.88 USD (+65.6%)
8 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Vaxcyte is a clinical-stage biopharmaceutical company developing next-generation conjugate vaccines for the prevention of bacterial diseases, with no marketed products and funding based on venture capital.
Key points
from its scores- ✓Good share-price trend7.3
- ✕Little or no dividend0.5
- ✕Little competitive advantage0.8
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsThe vaccine pipeline has high potential, but the lack of revenue and cash burn require additional funding, a high risk in the current rate environment.
Vaxcyte is a pre-revenue biotech with a solid balance sheet (liquidity 5.72) but no cash generation (FCF yield -4.9%) and deeply negative profitability (ROE -36.5%), reflecting its development stage and dependence on future approvals and funding.
The main risk is financing: with no revenue and a negative FCF yield, Vaxcyte depends on capital markets to continue operations, and higher US interest rates could dilute shareholders or limit its development capacity.
Context and risks
Vaxcyte is a development-stage biotech with no revenue or approved products, exposing it to inherent regulatory and financing risks. Its negative profitability and lack of cash generation make it dependent on capital markets, a risk aggravated by the current tightening of financial conditions.
Is Vaxcyte stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 3.5 | 4.1 | −14% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 110.88 USD, +65.6% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −8.9
- EV / EBITDA
- −7.4
- Price / book
- 3.5
- Market cap
- 10.0B USD
- Enterprise value
- 8.6B USD
Profitability
- ROE
- −36.5%
- ROA
- −22.6%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −485.8M USD
- FCF yield
- −4.9%
Solvency
- Total debt
- 115.4M USD
- Net debt
- −1.4B USD
- Cash
- 1.5B USD
- EBITDA
- −1.1B USD
- Net debt / EBITDA
- 1.19
- Debt / equity
- 4.19
- Current ratio
- 5.72
- Quick ratio
- 5.48
Growth
- EPS (TTM)
- −7.62 USD
- EPS (forward)
- −7.53 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 1.23
- Analyst consensus
- Strong buy (8)
- Target price
- 110.88 USD
- 52-week range
- 39.87 – 90.75
Recent news
All PCVX news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Vaxcyte
Is Vaxcyte stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 110.88 USD, +65.6% versus the price. This is not investment advice.
What score does Vaxcyte get on MeridIAn Screener?
It scores 2.7 out of 10, rank 2,101 of 2,130 (better than 1% of the companies analysed). Its strongest category is Momentum (7.3) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Vaxcyte worth on the stock market?
Its market capitalisation is 10.0B USD and its enterprise value, debt included, is 8.6B USD.
How much debt does Vaxcyte have?
It has more cash than debt: net cash of 1.4B USD.
Does Vaxcyte pay a dividend?
It pays no dividend, or almost none.
How has Vaxcyte stock performed over the last year?
It has risen 53.2% over the last year, excluding dividends. Over the last 52 weeks it has traded between 39.87 and 90.75 USD. Past performance does not guarantee future results.
What do analysts think of Vaxcyte?
8 analysts cover it; their average recommendation is “Strong buy” and their average target is 110.88 USD (+65.6% versus the price). It is an estimate, not market data.